Abstract
Kateryna Kom / Science Photo Library / Getty Images
Molecular diagnostics company MDx-Health announced that the New York State Department of Health granted approval for its liquid biopsy SelectMDx test for Prostate Cancer, now making it available to patients and physicians in all 50 states in the U.S.
SelectMDx is a urine-based molecular diagnostic designed to detect biomarkers that identify those men at higher risk of developing prostate cancer. According to company research published in the journals Urology Practice and the Journal of Urology, the test has the potential to decrease the number of unnecessary tissue biopsies and MRIs for prostate cancer diagnosis by as much as 50% and could potentially save as much as $500 million in annual healthcare costs.